Jane Street Group LLC Decreases Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Jane Street Group LLC cut its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 87.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,960 shares of the company's stock after selling 79,939 shares during the period. Jane Street Group LLC's holdings in Evolus were worth $132,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Evolus during the fourth quarter valued at about $49,000. Rhumbline Advisers boosted its position in Evolus by 2.2% during the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock valued at $885,000 after buying an additional 1,762 shares during the period. Principal Financial Group Inc. boosted its position in Evolus by 9.8% during the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock valued at $368,000 after buying an additional 2,989 shares during the period. Rice Hall James & Associates LLC boosted its holdings in shares of Evolus by 4.8% during the fourth quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock worth $10,469,000 after purchasing an additional 43,381 shares during the period. Finally, IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after purchasing an additional 4,709 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Trading Up 3.7%

EOLS stock traded up $0.37 during trading on Wednesday, reaching $10.24. The company had a trading volume of 1,562,895 shares, compared to its average volume of 736,288. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The company has a market cap of $660.23 million, a P/E ratio of -11.25 and a beta of 1.00. The business has a 50 day moving average of $10.30 and a 200 day moving average of $11.84. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Insider Buying and Selling

In other Evolus news, Director Albert G. White III bought 20,000 shares of the firm's stock in a transaction on Monday, June 9th. The stock was acquired at an average price of $9.45 per share, with a total value of $189,000.00. Following the completion of the purchase, the director now owns 50,378 shares of the company's stock, valued at approximately $476,072.10. This trade represents a 65.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 6,494 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $10.02, for a total transaction of $65,069.88. Following the sale, the chief financial officer now directly owns 167,089 shares of the company's stock, valued at $1,674,231.78. This trade represents a 3.74% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,353 shares of company stock valued at $881,251 over the last three months. Corporate insiders own 5.90% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on EOLS shares. BTIG Research started coverage on shares of Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Barclays increased their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.